Pacira signs Molteni to commercialize EXPAREL across EU and U.K.

Seeking Alpha··EUGBIT·Read original
2▲1 ▼0Impact / 5
Summary · why it matters

Pacira BioSciences signed an exclusive agreement with Molteni Farmaceutici to distribute and commercialize EXPAREL in the European Union and U.K. Under the deal, Pacira will receive an undisclosed upfront payment, a supply price, and royalties on future commercial sales in the licensed territories. Pacira will continue to manufacture EXPAREL, while Molteni will oversee regulatory, market access, and commercialization activities. Molteni plans to launch EXPAREL sequentially in Italy, Germany, Austria, and Poland, with plans to seek approval in Switzerland. The first commercial sale is expected in 2027.

Impact on assets 1

Health Care▲ · 1 stocks
Pacira BioSciences, Inc.
PCRX
▲ PositiveDemandrelevance

Pacira signs exclusive deal with Molteni to commercialize EXPAREL across the EU and U.K., expanding commercial reach for its product.

Off-coverage companies 1

Molteni FarmaceuticiPrivate▲ Positive
Demandrelevance

Molteni gains exclusive rights to distribute and commercialize EXPAREL in the EU and U.K., adding a product to its commercial portfolio.

© 2026 MarketIVNews